Incyte is a global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to meet serious unmet medical needs. The company is advancing a diversified selection of clinical candidates in oncology and inflammation and autoimmunity — the majority of which were discovered at Incyte, by Incyte scientists. Incyte has a presence in 13 countries and more than 1,300 employees — including 600 world-class scientists who are leading the field of biopharmaceutical research.
What have been the biggest obstacles your company has faced over the past three years, and how did you overcome them?
Like other biopharmaceutical companies, we have faced disappointments. Instead of focusing on negatives, we focus on applying the knowledge gained to inform our approach to advancing our portfolio of investigational therapies. Today, we have six late-stage products in development that we believe have the potential to improve outcomes for patients in need.
Looking back, what’s the biggest mistake you made and what would you do differently if you could?
One of the most difficult things to manage in a fast-growing company is the speed at which to force evolution. Changes that affect expansion, growth, diversification and culture can be difficult to balance but important for a company to move forward.
What is the most valuable lesson you’ve learned over the past three years?
By staying true to Incyte’s mission, no matter the ups and downs that may come, the dedication to develop innovative treatment for patients who have limited options drives our success.